The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-09 and is reviewed periodically as new material appears.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The Gustilo open fracture classification system is the most commonly used classification system for open fractures. It was created by Ramón Gustilo and Anderson, and then further expanded by Gustilo, Mendoza, and Williams. This system uses the amount of energy, the extent of soft-tissue injury and the extent of contamination for determination of fracture severity. Progression from grade 1 to 3C implies a higher degree of energy involved in the injury, higher soft tissue and bone damage and higher potential for complications. It is important to recognize that a Gustilo score of grade 3C implies vascular injury as well as bone and connective-tissue damage.
The Philippine cobra (Naja philippinensis) is one of the most venomous cobra species in the world based on murine LD50 studies. The average subcutaneous LD50 for this species is 0.20 mg/kg. The lowest LD50 reported value for this snake is 0.14 mg/kg SC, while the highest is 0.48 mg/kg SC. and the average venom yield per bite is 90–100 mg. The venom of the Philippine cobra is a potent postsynaptic neurotoxin which affects respiratory function and can cause neurotoxicity and respiratory paralysis, as the neurotoxins interrupt the transmission of nerve signals by binding to the neuromuscular junctions near the muscles. Research has shown its venom is purely a neurotoxin, with no apparent necrotizing components and no cardiotoxins. These snakes are capable of accurately spitting their venom at a target up to 3 metres (9.8 ft) away. Bites from this species produce prominent neurotoxicity and are considered especially dangerous. A study of 39 patients envenomed by the Philippine cobra was conducted in 1988. Neurotoxicity occurred in 38 cases and was the predominant clinical feature. Complete respiratory failure developed in 19 patients, and was often rapid in onset; in three cases, apnea occurred within just 30 minutes of the bite. There were two deaths, both in patients who were moribund upon arrival at the hospital. Three patients developed necrosis, and 14 individuals with systemic symptoms had no local swelling at all. Both cardiotoxicity and reliable nonspecific signs of envenoming were absent.
The Gateway Program is the planned expansion and renovation of the Northeast Corridor between Newark, New Jersey, and New York City to alleviate the bottleneck by allowing for refurbishment of the existing North River Tunnels and ultimately expanding the right-of-way to four tracks, doubling the capacity of Penn Station. Two new tunnels under the Hudson River would add 25 cross-Hudson train slots during rush hours. Some proposals anticipated a four-platform, seven-track expansion of Penn Station with a new annex to the south to take advantage of the new capacity, but current reconstruction plans envision increasing capacity through some limited through-running instead. The Gateway Program was unveiled in 2011, one year after the cancellation of the somewhat-similar Access to the Region's Core (ARC) project, and was originally projected to cost $13.5 billion and take 14 years to build. Construction of a "tunnel box" to preserve right-of-way on Manhattan's West Side began in September 2013. In 2015, Amtrak said that damage done to the existing trans-Hudson tunnels by Sandy had made their replacement urgent and reported that design work on the tunnel component was underway, estimating the project cost at $20 billion. A draft environmental impact statement on the Hudson Tunnel project was released in July 2017, but the first Trump administration delayed consideration of it. Unblocking the project was a stated priority of the Biden administration, and the project was approved in May 2021.
==== Organically sourced micronutrients ==== Micronutrients can be sourced from organic fertilizers as well. For example, composted pine bark is high in manganese and is sometimes used to fulfill that mineral requirement in conventional hydroponic solutions. To satisfy requirements for National Organic Programs, pulverized, unrefined minerals (e.g. Gypsum, Calcite, and glauconite) can also be added to satisfy a plant's nutritional needs.
== History == Peptide amphiphiles were developed in the 1990s. They were first described by the group of Matthew Tirrell in 1995. These first reported PA molecules were composed of two domains: one of lipophilic character and another of hydrophilic properties, which allowed self-assembly into sphere-like supramolecular structures as a result of the association of the lipophilic domains away from the solvent (hydrophobic effect), which resulted in the core of the nanostructure. The hydrophilic residues become exposed to the water, giving rise to a soluble nanostructure. Work in the laboratory of Samuel I. Stupp by Hartgerink et al., in the early 2000s, reported a new type of PA that are able to self-assemble into elongated nanostructures. These novel PAs contain three regions: a hydrophobic tail, a region of beta-sheet-forming amino acids, and a charged peptide epitope designed to allow solubility of the molecule in water. In addition, the PAs may contain a targeting or signaling epitope that allows the formed nanostructures to perform a biological function, either targeting or signaling, by interacting with living systems. The self-assembly mechanism of these PAs is a combination of hydrogen-bonding between beta-sheet forming amino acids and hydrophobic collapse of the tails to yield the formation of cylindrical micelles that present the peptide epitope at extremely high density at the nanofiber surface. By changing pH or adding counterions to screen the charged surfaces of fibers, gels can be formed.
Sources: en.wikipedia.org
Adult linear IgA disease Bullous pemphigoid Bullous lupus erythematosus Childhood linear IgA disease (chronic bullous disease of childhood) Cicatricial pemphigoid (benign mucosal pemphigoid, benign mucous membrane pemphigoid, ocular pemphigus, scarring pemphigoid) Dermatitis herpetiformis (Duhring disease) Dyshidrosis (recurrent vesicular palmoplantar dermatitis, acute vesiculobullous hand eczema, dyshidrotic dermatitis, pompholyx) Endemic pemphigus (endemic pemphigus foliaceus, fogo selvagem) Epidermolysis bullosa acquisita Grover's disease (benign papular acantholytic dermatosis, persistent acantholytic dermatosis, transient acantholytic dermatosis) IgA pemphigus Intraepidermal neutrophilic IgA dermatosis Localized cicatricial pemphigoid (Brunsting–Perry cicatricial pemphigoid) Paraneoplastic pemphigus Pemphigus erythematosus (Senear–Usher syndrome) Pemphigus foliaceus Pemphigus herpetiformis (acantholytic herpetiform dermatitis, herpetiform pemphigus, mixed bullous disease, pemphigus controlled by sulfapyridine) Pemphigoid nodularis Pemphigus vegetans Pemphigus vegetans of Hallopeau Pemphigus vegetans of Neumann Pemphigus vulgaris Vesicular pemphigoid Vulvar childhood pemphigoid
Chocolate contains polyphenols, especially flavan-3-ols (catechins) and smaller amounts of other flavonoids. It also contains alkaloids, such as theobromine, phenethylamine, and caffeine, which are under study for their potential effects in the body. These compounds are affected by the processing of cocoa, and the content in commercially available chocolate is highly variable.
MusclePharm owed vendors approximately $1.1 million in outstanding invoices and was short on funds to pay them the money. 2014 MusclePharm acquired BioZone Laboratories, which included its facility in Richmond, California. This acquisition included BioZone's QuSomes, HyperSorb and, EquaSome technologies, as well as various lines of products including the Arnold Schwarzenegger series in 2013. The acquisition was finalized in late 2013. MusclePharm sold Biozone to Valencia, CA-based Flavor Producers for $9.8 million in April 2016. 2013 MusclePharm Corp. announced plans to buy back $5 million of all common stock in December 2013. In 2013 MusclePharm Corporation completed a $12 million registered direct offering of its Series D Convertible Preferred Stock. The Frost Group, LLC, headed by Miami entrepreneur, and billionaire, Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million. 2012 Marina Ventures sought to force MusclePharm's sale of 21 million shares of common stock. Inter-Mountain Capital sued MusclePharm for alleged failure to sell, seeking damages of $4 million. John's Lone Star Distribution alleged in a suit that MusclePharm entered into illegal price discrimination contracts with a Lone Star competitor with the intention of removing Lone Star from the market. NSF International notified the public that a MusclePharm product improperly bore the "NSF Certified for Sport" mark.
Papillomas and warts/verrucae: They are caused by various strains of the human papilloma virus (HPV) of which there are more than 100 strains but usually due to HPV types 6 and 11. Papillomas are mostly spiky, finger like projections, or cauliflower head rounded lobular shaped. Usually painless and singular. Verrucae usually appear on the lips. Verrucae vulgaris is associated with HPV types 2 and 4. HPV types 16 and 18, designated high risk due to association with cancers, do not present like this in the oral mucosa but as white patches. Multifocal epithelial hyperplasia (Heck disease) is rare, usually familial, swellings appear in multiples and are more common to some Native American and Inuit groups. Verruciform xanthoma, a rare lesion which may resemble papilloma, is often white due to hyperkeratosis, usually appear in 50-70 year age group, commonly on the gingivae. They may be mistaken for papilloma or verrucous leukoplakia but are benign.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.